{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T22:36:43Z","timestamp":1775687803053,"version":"3.50.1"},"reference-count":80,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["FOR"],"award-info":[{"award-number":["FOR"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["He 1602\/13-2"],"award-info":[{"award-number":["He 1602\/13-2"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["MH"],"award-info":[{"award-number":["MH"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.coph.2018.12.007","type":"journal-article","created":{"date-parts":[[2019,2,13]],"date-time":"2019-02-13T00:44:44Z","timestamp":1550018684000},"page":"34-43","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"special_numbering":"C","title":["Pharmacological advances in pemphigoid"],"prefix":"10.1016","volume":"46","author":[{"given":"Roberto","family":"Maglie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Hertl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2018.12.007_bib0005","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s12016-017-8633-4","article-title":"Autoimmune subepidermal bullous diseases of the skin and mucosae: clinical features, diagnosis, and management","volume":"54","author":"Amber","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.coph.2018.12.007_bib0010","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.3389\/fimmu.2017.01752","article-title":"BP180 is critical in the autoimmunity of bullous pemphigoid","volume":"8","author":"Liu","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.coph.2018.12.007_bib0015","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1038\/jid.2011.180","article-title":"Demonstration of epitope-spreading phenomena in bullous pemphigoid: results of a prospective multicenter study","volume":"131","author":"Di Zenzo","year":"2011","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.coph.2018.12.007_bib0020","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.clim.2008.04.012","article-title":"Multicenter prospective study of the humoral autoimmune response in bullous pemphigoid","volume":"128","author":"Di Zenzo","year":"2008","journal-title":"Clin Immunol"},{"key":"10.1016\/j.coph.2018.12.007_bib0025","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.jid.2017.11.031","article-title":"Eosinophils mediate tissue injury in the autoimmune skin disease bullous pemphigoid","volume":"138","author":"Lin","year":"2018","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.coph.2018.12.007_sbref0030","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1001\/jamadermatol.2016.3357","article-title":"Correlation of Serum Levels of IgE Autoantibodies Against BP180 With Bullous Pemphigoid Disease Aserum levels of IgE autoantibodies against BP180 with bullous pemphigoid disease activity","volume":"153","author":"van Beek","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.coph.2018.12.007_bib0035","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s12026-017-8975-2","article-title":"Subepidermal autoimmune bullous diseases: overview, epidemiology, and associations","volume":"66","author":"Kridin","year":"2018","journal-title":"Immunol Res"},{"key":"10.1016\/j.coph.2018.12.007_bib0040","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3389\/fmed.2018.00220","article-title":"The growing incidence of bullous pemphigoid: overview and potential explanations","volume":"5","author":"Kridin","year":"2018","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.coph.2018.12.007_bib0045","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.jaad.2017.12.038","article-title":"Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid: retrospective multicenter case-control study from France and Switzerland","volume":"78","author":"Benzaquen","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.coph.2018.12.007_bib0050","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/jid.2010.301","article-title":"Risk factors for bullous pemphigoid in the elderly: a prospective case-control study","volume":"131","author":"Bastuji-Garin","year":"2011","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.coph.2018.12.007_bib0055","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1001\/2013.jamadermatol.376","article-title":"The associations between bullous pemphigoid and drug use: a UK case-control study","volume":"149","author":"Lloyd-Lavery","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.coph.2018.12.007_sbref0060","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1001\/jamadermatol.2018.2352","volume":"154","author":"Kridin","year":"2018","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.coph.2018.12.007_bib0065","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1097\/CMR.0000000000000500","article-title":"Anti-programmed cell death-1 therapy-associated bullous disorders: a systematic review of the literature","volume":"28","author":"Zhao","year":"2018","journal-title":"Melanoma Res"},{"key":"10.1016\/j.coph.2018.12.007_bib0070","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jaad.2017.10.035","article-title":"Nonbullous pemphigoid: a systematic review","volume":"78","author":"Lamberts","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.coph.2018.12.007_bib0075","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jaad.2011.06.032","article-title":"Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts","volume":"66","author":"Murrell","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.coph.2018.12.007_bib0080","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/j.1365-2133.2009.09266.x","article-title":"IgG autoantibody reactivity against bullous pemphigoid (BP) 180 and BP230 in elderly patients with pruritic dermatoses","volume":"161","author":"Feliciani","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.coph.2018.12.007_bib0085","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.clim.2012.02.003","article-title":"IgE recognition of bullous pemphigoid (BP)180 and BP230 in BP patients and elderly individuals with pruritic dermatoses","volume":"143","author":"Fania","year":"2012","journal-title":"Clin Immunol"},{"key":"10.1016\/j.coph.2018.12.007_bib0090","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00403-018-1817-9","article-title":"BPDAI and ABSIS correlate with serum anti-BP180 NC16A IgG but not with anti-BP230 IgG in patients with bullous pemphigoid","volume":"310","author":"Daneshpazhooh","year":"2018","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.coph.2018.12.007_bib0095","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1159\/000362717","article-title":"Assessment of bullous pemphigoid disease area index during treatment: a prospective study of 30 patients","volume":"229","author":"Levy-Sitbon","year":"2014","journal-title":"Dermatology"},{"key":"10.1016\/j.coph.2018.12.007_bib0100","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1111\/bjd.16249","article-title":"A possible association between BP230-type bullous pemphigoid and dementia: a report of two cases in elderly patients","volume":"178","author":"Zheng","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.coph.2018.12.007_bib0105","article-title":"Diagnosis of anti-laminin gamma-1 pemphigoid by immunoblot analysis","author":"Solimani","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.coph.2018.12.007_bib0110","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1111\/bjd.13717","article-title":"Management of bullous pemphigoid: the European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology","volume":"172","author":"Feliciani","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.coph.2018.12.007_bib0115","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa011592","article-title":"A comparison of oral and topical corticosteroids in patients with bullous pemphigoid","volume":"346","author":"Joly","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2018.12.007_bib0120","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1111\/bjd.15649","article-title":"An open, multicentre, randomized clinical study in patients with bullous pemphigoid comparing methylprednisolone and azathioprine with methylprednisolone and dapsone","volume":"177","author":"Sticherling","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.coph.2018.12.007_bib0125","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/1346-8138.14503","article-title":"Mortality in bullous pemphigoid: a systematic review and meta-analysis of standardized mortality ratios","volume":"45","author":"Kridin","year":"2018","journal-title":"J Dermatol"},{"key":"10.1016\/j.coph.2018.12.007_bib0130","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1111\/jdv.14345","article-title":"Doxycycline as an anti-inflammatory agent: updates in dermatology","volume":"31","author":"Henehan","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.coph.2018.12.007_bib0135","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.2174\/1567205013666160819124206","article-title":"The anti-inflammatory role of minocycline in Alzheimer\u2019s disease","volume":"13","author":"Budni","year":"2016","journal-title":"Curr Alzheimer Res"},{"key":"10.1016\/j.coph.2018.12.007_bib0140","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0190-9622(08)81937-8","article-title":"Treatment of generalized bullous pemphigoid with oral tetracycline","volume":"30","author":"Sanchez Miralles","year":"1994","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.coph.2018.12.007_bib0145","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1001\/archderm.1994.01690060083010","article-title":"Nicotinamide and tetracycline therapy of bullous pemphigoid","volume":"130","author":"Fivenson","year":"1994","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.coph.2018.12.007_sbref0150","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S0140-6736(17)30560-3","article-title":"Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial","volume":"389","author":"Williams","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2018.12.007_sbref0155","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/bjd.16006","article-title":"Doxycycline compared with prednisolone therapy for patients with bullous pemphigoid: cost-effectiveness analysis of the BLISTER trial","volume":"178","author":"Mason","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.coph.2018.12.007_bib0160","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(17)31808-1","article-title":"The BLISTER study: possible overestimation of tetracycline efficacy","volume":"390","author":"Sladden","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2018.12.007_bib0165","doi-asserted-by":"crossref","first-page":"e534","DOI":"10.1111\/jdv.14399","article-title":"Chronic exposure to tetracyclines and subsequent diagnosis for non-melanoma skin cancer in a large Midwestern U.S. patient population","volume":"31","author":"Vakharia","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.coph.2018.12.007_bib0170","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1007\/s40265-018-0976-5","article-title":"Targeted therapies for autoimmune bullous diseases: current status","volume":"78","author":"Amber","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.coph.2018.12.007_bib0175","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jid.2018.02.020","article-title":"Modes of action of intravenous immunoglobulin in bullous pemphigoid","volume":"138","author":"Li","year":"2018","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.coph.2018.12.007_bib0180","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.3389\/fimmu.2017.01669","article-title":"Anti-idiotypic antibodies against BP-IgG prevent type XVII collagen depletion","volume":"8","author":"Kamaguchi","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.coph.2018.12.007_bib0185","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1016\/j.jid.2018.01.005","article-title":"Intravenous IgG reduces pathogenic autoantibodies, serum IL-6 levels, and disease severity in experimental bullous pemphigoid models","volume":"138","author":"Sasaoka","year":"2018","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.coph.2018.12.007_bib0190","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1684\/ejd.2012.1717","article-title":"High-dose intravenous immunoglobulin in the treatment of adult patients with bullous pemphigoid","volume":"22","author":"Gaitanis","year":"2012","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.coph.2018.12.007_bib0195","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1067\/mjd.2001.116337","article-title":"Intravenous immunoglobulin therapy for patients with bullous pemphigoid unresponsive to conventional immunosuppressive treatment","volume":"45","author":"Ahmed","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.coph.2018.12.007_sbref0200","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jdermsci.2016.11.003","article-title":"A randomized double-blind trial of intravenous immunoglobulin for bullous pemphigoid","volume":"85","author":"Amagai","year":"2017","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.coph.2018.12.007_bib0205","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1038\/jid.2013.236","article-title":"Association of serum B-cell activating factor level and proportion of memory and transitional B cells with clinical response after rituximab treatment of bullous pemphigoid patients","volume":"133","author":"Hall","year":"2013","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.coph.2018.12.007_bib0210","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1111\/j.1468-3083.2010.03889.x","article-title":"Bullous and mucous membrane pemphigoid show a mixed response to rituximab: experience in seven patients","volume":"25","author":"Lourari","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.coph.2018.12.007_bib0215","first-page":"672","article-title":"Treatment of bullous pemphigoid with rituximab: critical analysis of the current literature","volume":"12","author":"Shetty","year":"2013","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.coph.2018.12.007_bib0220","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3389\/fimmu.2018.00248","article-title":"Effectiveness and safety of rituximab in recalcitrant pemphigoid diseases","volume":"9","author":"Lamberts","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.coph.2018.12.007_bib0225","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/bjd.13633","article-title":"First-line combination therapy with rituximab and corticosteroids provides a high complete remission rate in moderate-to-severe bullous pemphigoid","volume":"173","author":"Cho","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.coph.2018.12.007_sbref0230","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jaad.2015.11.030","article-title":"Treatment of recalcitrant bullous pemphigoid (BP) with a novel protocol: Aa retrospective study with a 6-year follow-up","volume":"74","author":"Ahmed","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.coph.2018.12.007_bib0235","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/jdv.12175","article-title":"Treatment of severe autoimmune blistering skin diseases with combination of protein A immunoadsorption and rituximab: a protocol without initial high dose or pulse steroid medication","volume":"28","author":"Kolesnik","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.coph.2018.12.007_bib0240","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.jaad.2014.06.014","article-title":"Treatment of bullous pemphigoid with adjuvant immunoadsorption: a case series","volume":"71","author":"Kasperkiewicz","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.coph.2018.12.007_bib0245","first-page":"1109","article-title":"Adjuvant treatment of severe\/refractory bullous pemphigoid with protein A immunoadsorption","volume":"16","author":"Hubner","year":"2018","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.coph.2018.12.007_sbref0250","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1111\/bjd.15924","article-title":"IgE autoreactivity in bullous pemphigoid: eosinophils and mast cells as major targets of pathogenic immune reactants","volume":"177","author":"Freire","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.coph.2018.12.007_bib0255","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1001\/archdermatol.2012.1604","article-title":"Successful treatment of bullous pemphigoid with omalizumab","volume":"148","author":"London","year":"2012","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.coph.2018.12.007_bib0260","doi-asserted-by":"crossref","first-page":"523","DOI":"10.7754\/Clin.Lab.2013.130642","article-title":"Anti-IgE monoclonal antibody (omalizumab) is effective in treating bullous pemphigoid and its effects on soluble CD200","volume":"60","author":"Yalcin","year":"2014","journal-title":"Clin Lab"},{"key":"10.1016\/j.coph.2018.12.007_bib0265","doi-asserted-by":"crossref","first-page":"284","DOI":"10.2340\/00015555-2845","article-title":"Biological and clinical response to omalizumab in a patient with bullous pemphigoid","volume":"98","author":"Menzinger","year":"2018","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.coph.2018.12.007_sbref0270","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1111\/jdv.13758","article-title":"Successful treatment of bullous pemphigoid with omalizumab as corticosteroid-sparing agent: report of two cases and review of literature","volume":"30","author":"Balakirski","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.coph.2018.12.007_bib0275","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.jaad.2014.04.053","article-title":"Omalizumab therapy for bullous pemphigoid","volume":"71","author":"Yu","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.coph.2018.12.007_sbref0280","article-title":"Rituximab and omalizumab for the treatment of bullous pemphigoid: a systematic review","author":"Kremer","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.coph.2018.12.007_bib0285","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00403-017-1789-1","article-title":"IgE autoantibodies and their association with the disease activity and phenotype in bullous pemphigoid: a systematic review","volume":"310","author":"Saniklidou","year":"2018","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.coph.2018.12.007_bib0290","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/tan.12960","article-title":"A multi-hit hypothesis of bullous pemphigoid and associated neurological disease: is HLA-DQB103:01, a potential link between immune privileged antigen exposure and epitope spreading?","volume":"89","author":"Amber","year":"2017","journal-title":"HLA"},{"key":"10.1016\/j.coph.2018.12.007_bib0295","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.4049\/jimmunol.176.3.2015","article-title":"Autoreactive T and B cells from bullous pemphigoid (BP) patients recognize epitopes clustered in distinct regions of BP180 and BP230","volume":"176","author":"Thoma-Uszynski","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.coph.2018.12.007_bib0300","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1172\/JCI3335","article-title":"Identification and characterization of autoreactive T cell responses to bullous pemphigoid antigen 2 in patients and healthy controls","volume":"102","author":"Budinger","year":"1998","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coph.2018.12.007_bib0305","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1046\/j.1523-1747.2002.19529.x","article-title":"Severity and phenotype of bullous pemphigoid relate to autoantibody profile against the NH2- and COOH-terminal regions of the BP180 ectodomain","volume":"119","author":"Hofmann","year":"2002","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.coph.2018.12.007_bib0310","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/S0923-1811(02)00067-1","article-title":"Th1, Th2 and Th3 cytokines in the pathogenesis of bullous pemphigoid","volume":"30","author":"Giomi","year":"2002","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.coph.2018.12.007_bib0315","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.clim.2006.03.014","article-title":"Increased expression of Th2-associated chemokines in bullous pemphigoid disease. Role of eosinophils in the production and release of these chemokines","volume":"120","author":"Gounni Abdelilah","year":"2006","journal-title":"Clin Immunol"},{"key":"10.1016\/j.coph.2018.12.007_sbref0320","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3389\/fmed.2018.00201","article-title":"The role of eosinophils in bullous pemphigoid: a developing model of eosinophil pathogenicity in mucocutaneous disease","volume":"5","author":"Amber","year":"2018","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.coph.2018.12.007_bib0325","doi-asserted-by":"crossref","first-page":"306","DOI":"10.3389\/fmed.2018.00306","article-title":"Perspective from the 5th international pemphigus and pemphigoid foundation scientific conference","volume":"5","author":"Lee","year":"2018","journal-title":"Front Med (Lausanne)"},{"issue":"10","key":"10.1016\/j.coph.2018.12.007_sbref0330","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1001\/jamadermatol.2018.2526","article-title":"Dupilumab for the treatment of recalcitrant bullous pemphigoid","volume":"154","author":"Kaye","year":"2018","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.coph.2018.12.007_sbref0335","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1038\/jid.2014.263","article-title":"Innate immune cell-produced IL-17 sustains inflammation in bullous pemphigoid","volume":"134","author":"Le Jan","year":"2014","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.coph.2018.12.007_sbref0340","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jaut.2018.09.003","article-title":"IL -17A is functionally relevant and a potential therapeutic target in bullous pemphigoid","volume":"96","author":"Chakievska","year":"2019","journal-title":"J Autoimmun"},{"key":"10.1016\/j.coph.2018.12.007_sbref0345","doi-asserted-by":"crossref","DOI":"10.1038\/srep18001","article-title":"Integrating longitudinal serum IL-17 and IL-23 follow-up, along with autoantibodies variation, contributes to predict bullous pemphigoid outcome","volume":"5","author":"Plee","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.coph.2018.12.007_bib0350","doi-asserted-by":"crossref","first-page":"e228","DOI":"10.1111\/jdv.14002","article-title":"A successful treatment with ustekinumab in a case of relapsing bullous pemphigoid associated with psoriasis","volume":"31","author":"Loget","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.coph.2018.12.007_bib0355","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1111\/bjd.12163","article-title":"A successful treatment with ustekinumab in a case of antilaminin-gamma1 pemphigoid associated with psoriasis","volume":"168","author":"Majima","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.coph.2018.12.007_bib0360","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1684\/ejd.2016.2888","article-title":"Bullous pemphigoid during ustekinumab therapy in a psoriatic patient","volume":"27","author":"Onsun","year":"2017","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.coph.2018.12.007_bib0365","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.jdcr.2015.07.014","article-title":"Bullous pemphigoid during ustekinumab therapy","volume":"1","author":"Le Guern","year":"2015","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.coph.2018.12.007_bib0370","doi-asserted-by":"crossref","first-page":"158","DOI":"10.12788\/j.sder.2018.047","article-title":"IL-23 inhibitors for moderate-to-severe psoriasis","volume":"37","author":"Ibler","year":"2018","journal-title":"Semin Cutan Med Surg"},{"key":"10.1016\/j.coph.2018.12.007_bib0375","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jaci.2016.08.012","article-title":"Bullous pemphigoid outcome is associated with CXCL10-induced matrix metalloproteinase 9 secretion from monocytes and neutrophils but not lymphocytes","volume":"139","author":"Riani","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.coph.2018.12.007_sbref0380","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1038\/jid.2013.91","article-title":"Methylprednisolone blocks autoantibody-induced tissue damage in experimental models of bullous pemphigoid and epidermolysis bullosa acquisita through inhibition of neutrophil activation","volume":"133","author":"Hellberg","year":"2013","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.coph.2018.12.007_sbref0385","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.jid.2016.12.021","article-title":"The leukotriene B4 and its receptor BLT1 act as critical drivers of neutrophil recruitment in murine bullous pemphigoid-like epidermolysis bullosa acquisita","volume":"137","author":"Sezin","year":"2017","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.coph.2018.12.007_sbref0390","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.smim.2018.03.002","article-title":"The critical role of C5a as an initiator of neutrophil-mediated autoimmune inflammation of the joint and skin","volume":"37","author":"Sadik","year":"2018","journal-title":"Semin Immunol"},{"key":"10.1016\/j.coph.2018.12.007_sbref0395","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jid.2017.08.030","article-title":"The Anti-C1s Antibody TNT003 Prevents Complement Activation in the Skin Induced by Bullous Pemphigoid Autoantibodies","volume":"138","author":"Kasprick","year":"2018","journal-title":"J Invest Dermatol"},{"issue":"4","key":"10.1016\/j.coph.2018.12.007_sbref0400","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/cpt.1111","article-title":"A Randomized, First-in-Human, Healthy Volunteer Trial of sutimlimab, a Humanized Antibody for the Specific Inhibition of the Classical Complement Pathway","volume":"104","author":"Bartko","year":"2018","journal-title":"Clin Pharmacol Ther"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489218300973?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489218300973?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T06:50:43Z","timestamp":1761461443000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489218300973"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":80,"alternative-id":["S1471489218300973"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2018.12.007","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological advances in pemphigoid","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2018.12.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}